Pfizer Inc and BioNTech SE on Saturday proposed expanding their Phase 3 Covid-19 vaccine trial to about 44,000 participants, while increasing the diversity of the trial population. — Reuters pic
Drugmaker AstraZeneca also said on Saturday it has resumed British clinical trials of its Covid-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs. “There is still some caution in markets because US virus numbers appear to be picking up again in some states,” said Seema Shah, chief strategist at Principal Global Investors.
MSCI’s benchmark for global equity markets rose 1.17 per cent to 572.57. In Europe, the broad FTSEurofirst 300 index edged up 0.07 per cent to 1,429 as losses in the energy sector offset surging travel and technology stocks that were boosted by the vaccine news.